The Future of Healthcare is Preventive – And Powered by AI
Executive leaders look to scalable, imaging-driven diagnostics to accelerate early intervention and reduce system strain
As health systems navigate rising patient demand, aging populations, and unsustainable care costs, executive focus is shifting from reactive treatment to preventive intelligence. At the center of this shift is artificial intelligence—specifically, platforms designed to detect diseases before symptoms emerge.
One of the most promising applications is in diagnostic imaging, where AI can now analyze radiological data in real time, uncover subtle signs of disease, and support clinical decisions long before traditional workflows would trigger escalation.
Hugo Raposo, a Canadian digital health strategist and former Chief Architect of a provincial modernization initiative, is among the thought leaders spearheading this evolution.
'We can't afford a future where detection starts only after symptoms appear,' Raposo said. 'AI makes it possible to reorient our entire clinical model around early warning—moving us from system overload to system foresight.'
Executive Pressure: Why Preventive Diagnostics is a Strategic Imperative
In both Canada and the United States, wait times for imaging continue to rise, specialist access remains uneven, and late-stage diagnoses are driving up costs. According to the Canadian Institute for Health Information, non-urgent MRI waits in some provinces now exceed 90 days.
What's emerging is a new class of AI platforms designed not just for efficiency, but for proactive risk detection across imaging modalities—from chest X-rays to brain MRIs and retinal scans. These tools serve as always-on, pattern-seeking copilots that help:
Executives are now exploring how such tools can become core to digital health strategy, not just clinical augmentation.
Hugo Raposo's Vision: Scalable, Ethical AI for System-Wide Preventive Impact
Raposo's platform—currently deployed across hospital and community clinics in Ontario—focuses on turning diagnostic imaging into a predictive capability. It is built to integrate with existing PACS/EHR environments and works both in urban health networks and bandwidth-limited rural regions.
Key attributes include:
Importantly, Raposo frames this not as an IT solution, but as a strategic enabler of access, quality, and sustainability.
'The ROI is no longer just about efficiency. It's about reducing emergency interventions, preventing chronic progression, and giving leadership the levers to shift from volume to value,' he said.
More on Hugo Raposo
From Boardroom to Bedside: Aligning with National and Global Priorities
Global policymakers are already signaling the importance of diagnostic AI. The U.S. HHS AI Strategy, CMS value-based care models, and WHO's AI ethics guidance all emphasize the need to deploy AI responsibly across care ecosystems.
Raposo's work aligns directly with these goals:
For CIOs and health CEOs, this represents a new decision point: not whether to adopt AI—but how to align it with enterprise risk, public health readiness, and long-term clinical quality.
What's Ahead: Predictive Imaging as a Platform Strategy
Beyond static interpretation, Raposo is working to integrate imaging data with lab results, pathology, and even ambient documentation. The goal: to create a multimodal, longitudinal diagnostic layer that can inform triage, treatment planning, and population health simultaneously.
Upcoming capabilities include:
'Imaging isn't just diagnostic—it's becoming foundational infrastructure for predictive care,' Raposo emphasized. 'In five years, AI won't be a feature—it will be a precondition for delivering safe, timely, and cost-effective healthcare.'
LinkedIn: linkedin.com/in/hugoraposo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
2 Dividend Stocks to Buy for Decades of Passive Income
Key Points Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits for a long time to come. That's thanks to their solid businesses and promising product pipelines. In 2013, AbbVie (NYSE: ABBV) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (NYSE: ABT). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes. That likely won't change soon. These healthcare leaders should continue to perform well and reward shareholders with dividend increases for a long time. Read on to find out more. 1. AbbVie AbbVie is a pharmaceutical leader with a large portfolio of approved products, none more important than a duo of immunology medicines: Skyrizi and Rinvoq. In the first quarter, the company's revenue increased by 8.4% year over year to $13.3 billion, while its adjusted earnings per share came in at $2.46, 6.5% higher than the year-ago period. These results are all the more impressive considering AbbVie faced a major patent cliff just two years ago; however, it has since recovered, largely thanks to Skyrizi and Rinvoq. The former generated $3.4 billion in sales during the period, representing a 70.5% year-over-year increase. Rinvoq's revenue came in at $1.7 billion, 57.2% higher than the year-ago period. Management predicts their combined annual sales will exceed $31 billion by 2027. Not only is that significantly higher than the $17.7 billion they racked up last year, it's also $4 billion higher than their previous guidance. Skyrizi and Rinvoq are expected to drive top-line growth well into the 2030s. Although they will eventually lose patent protection, they demonstrate AbbVie's ability to navigate even the biggest patent cliffs, a quality that is essential for any pharmaceutical company to thrive over the long term. AbbVie has other products that help drive revenue growth, and, equally important, it has a deep pipeline that it routinely strengthens through acquisitions. In March, the company announced a licensing deal with Denmark-based Gubra A/S for GUB014295, an investigational weight management therapy. AbbVie paid $350 million up front for this candidate, with potential milestones of $1.9 billion, not including royalties. AbbVie entered the fast-growing weight loss market with this move; GUB014295 might not pan out, but AbbVie's large pipeline, with approximately 90 products in development, should allow it to launch brand-new products frequently, navigate patent cliffs, and remain successful over the long run. Now turning to the company's dividend, AbbVie has increased its payouts by 310% since 2013. And counting the time it spent under Abbott Laboratories' name, AbbVie is a Dividend King with 53 consecutive years of payout increases. These facts, from AbbVie's underlying business to the company's dividend track record, point to a company capable of sustaining a passive income program for a long time. 2. Abbott Laboratories Abbott Laboratories is best known for its leadership in the medical device space, where it markets dozens of products across multiple therapeutic areas. The company also operates a diagnostic business and has a presence in the pharmaceutical and nutrition industries. Abbott Laboratories' operations are diversified, which can help it overcome challenges in specific segments. That's one of the company's strengths. Here's another: Abbott Laboratories has been a leader in the highly regulated healthcare sector for decades. The company has built a solid reputation with physicians and consumers, all of whom are more likely to gravitate toward the brands they know and trust. In the medical device field, Abbott is a trusted brand. And thanks to its vast portfolio, it generates consistent revenue and earnings. Abbott's biggest growth driver in recent years has been its diabetes care segment, led by its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. As the company noted, the FreeStyle Libre has become the most successful medical device in history in terms of dollar sales. That's no small feat. Yet there is still massive whitespace ahead, since only a small portion of the world's diabetics use CGM technology despite its advantages. Abbott's work in this niche should provide a powerful long-term tailwind, but there will be many others. The company boasts other growth drivers, including its structural heart segment, where it markets a range of successful devices, such as its MitraClip device, a leader in its mitral valve repair niche. Beyond any single product, Abbott Laboratories has a proven track record as an innovator and should continue launching newer and better ones. Lastly, Abbott is also a Dividend King, and over the past decade, it has increased its payouts by almost 146%. Abbott Laboratories' business is built to last. Investors who purchase the company's shares today can expect consistent dividend growth over the long term. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025
CTV News
2 hours ago
- CTV News
A boy with a brain injury fights for his life in Gaza's decimated health system
Three-year-old Amr al-Hams, who has brain damage caused by an Israeli strike on his family's tent in April, lies in a bed at Nasser Hospital in Khan Younis, Gaza Strip, Wednesday, June 25, 2025. (AP Photo/Mariam Dagga) Content warning: This story includes graphic descriptions. Reader discretion is advised. BEIRUT — It's as if the whole weight of Israel's war in Gaza has fallen on Amr al-Hams. The three-year-old has shrapnel in his brain from an Israeli strike on his family's tent. His pregnant mother was killed. His father is paralyzed by grief over the death of his longtime sweetheart. Now the boy is lying in a hospital bed, unable to speak, unable to move, losing weight, while doctors don't have the supplies to treat his brain damage or help in his rehabilitation after a weekslong blockade and constant bombardment. Recently out of intensive care, Amr's frail body twists in visible pain. His wide eyes dart around the room. His aunt is convinced he's looking for his mother. He can't speak, but she believes he is trying to say 'mom.' 'I am trying as much as I can. It is difficult,' said his aunt Nour al-Hams, his main caregiver, sitting next to him on the bed in Khan Younis' Nasser Hospital in southern Gaza. 'What he is living through is not easy.' To reassure him, his aunt sometimes says his mother will be back soon. Other times, she tries to distract him, handing him a small ball. The war has decimated the health system The war began Oct. 7, 2023, when Hamas-led militants stormed into Israel and killed some 1,200 people, mostly civilians, and took 251 people captive. Israel's retaliatory campaign has killed over 57,000 Palestinians, according to Gaza's Health Ministry, which says women and children make up most of the dead but does not specify how many were fighters or civilians. Nearly 21 months into the conflict that displaced the vast majority of Gaza's 2.3 million people, it is nearly impossible for the critically wounded to get the care they need, doctors and aid workers say. The health care sector has been decimated: Nearly half of the territory's 36 hospitals have been put out of service. Daily bombings and strikes overwhelm the remaining facilities, which are operating only partially. They struggle with shortages of anything from fuel, gauze and sutures to respirators or scanners that have broken down and can't be replaced. Israeli forces have raided and besieged medical facilities, claiming Hamas militants have used them as command centers. Doctors have been killed or were displaced, unable to reach hospitals because of continued military operations. For more than 2 1/2 months, Israel blocked all food, medicine and other supplies from entering Gaza, accusing Hamas of siphoning off aid to fund its military activities, though the UN said there was no systematic diversion. The population was pushed toward famine. Since mid-May, Israel has allowed in a trickle of aid, including medical supplies. Gaza's Health Ministry estimates that 33,000 children have been injured during the war, including 5,000 requiring long-term rehabilitation and critical care. Over 1,000 children, like Amr, are suffering from brain or spinal injuries or amputated limbs. 'Gaza will be dealing with future generations of kids living with all sorts of disabilities, not just brain, but limb disabilities that are consequences of amputation that could have been prevented if the health system was not under the pressures it is under, wasn't systematically targeted and destroyed as it was,' said Tanya Haj-Hassan, a pediatric intensive care specialist who has volunteered multiple times in Gaza with international medical organizations. A fateful journey north In April, one week before her due date, Amr's mother, Inas, persuaded her husband to visit her parents in northern Gaza. They trekked from the tent they lived in on Gaza's southern coast to the tent where her parents live. They were having an evening meal when the strike hit. Amr's mother and her unborn baby, his grandfather and his brother and sister were killed. Amr was rushed to the ICU at Indonesian Hospital, the largest in northern Gaza. A scan confirmed shrapnel in his brain and reduced brain function. A breathing tube was inserted into his throat. 'He is three. Why should he bear the weight of a rocket?' his aunt asked. His father, Mohammed, was too stunned to even visit the ICU. His wife had been the love of his life since childhood, the aunt said. He barely spoke. Doctors said Amr needed advanced rehabilitation. But while he was at the hospital, Israeli forces attacked the facility — encircling its premises and causing damage to its communication towers, water supplies and one of its wards. Evacuation orders were issued for the area, and patients were transferred to Shifa Hospital in Gaza City. Another treacherous journey But Shifa was overwhelmed with mass casualties, and staff asked the family to take Amr south, even though no ambulances or oxygen tanks could be spared. The father and aunt had to take Amr, fresh out of ICU with the tube in his throat, in a motorized rickshaw for the 25-kilometre (15-mile) drive to Nasser Hospital. Amr was in pain, his oxygen levels dropped. He was in and out of consciousness. 'We were reading the Quran all along the road,' said his aunt, praying they would survive the bombings and Amr the bumpy trip without medical care. About halfway, an ambulance arrived. Amr made it to Nasser Hospital with oxygen blood levels so low he was again admitted to ICU. Unable to get the care he needs Still, Nasser Hospital could not provide Amr with everything he needed. Intravenous nutrients are not available, Nasser's head of pediatrics, Dr. Ahmed al-Farra, said. The fortified milk Amr needed disappeared from the market and the hospital after weeks of Israel's blockade. He has lost about half his weight. When he came out of the ICU, Nour shared his bed with him at night and administered his medication. She grinds rice or lentils into a paste to feed him through a syringe connected to his stomach. 'We have starvation in Gaza. There is nothing to eat,' said his aunt, who is a trained nurse. 'There is nothing left.' The care Amr has missed is likely to have long-term effects. Immediate care for brain injuries is critical, Haj-Hassan said, as is follow-up physical and speech therapy. Since the Israeli blockade on Gaza began in March, 317 patients, including 216 children, have left the territory for medical treatment alongside nearly 500 of their companions, according to the World Health Organization. Over 10,000 people, including 2,500 children, await evacuation. Amr is one of them. COGAT, the Israeli military body in charge of civilian affairs in Gaza, coordinates medical evacuations after receiving requests from countries that will take the patients and security screenings. In recent weeks, over 2,000 patients and their companions have left for treatment, COGAT said, without specifying the time period. Tess Ingram, spokesperson for the UN children's agency, said the only hope for many critically injured who remain in Gaza is to get out. Countries need to 'open their hearts, open their doors and open their hospitals to children who survived the unimaginable and are now languishing in pain,' she said. Amr's aunt reads his every move. He is unhappy with his diapers, she said. He outgrew them long ago. He was a smart kid, now he cries 'feeling sorry for himself,' said Nour. He gets seizures and needs tranquilizers to sleep. 'His brain is still developing. What can they do for him? Will he be able to walk again?' Nour asked. 'So long as he is in Gaza, there is no recovery for him.' Sarah El Deeb, The Associated Press
National Post
3 hours ago
- National Post
Chris Selley: We aren't slaves to AI, unless we want to be
Article content Immediate disbarment seems much more appropriate to me for any lawyer caught faking precedent — AI-generated or otherwise — but ChatGPT tells me that's unreasonable. Someday, though, presumably, this is going to lead to a truly disastrous outcome. That goes for every profession, not just the law. Article content I have a suspicion — or maybe it's more of a hope — that in 25 years we'll look back on the AI craze and chuckle at our own gullibility. It's not that it's useless; Google's AI-generated search results are a hell of a lot more useful than its actual search engine, if only because Google seems intent on making its actual search engine non-functional. AI can provide interesting information and answers — but then, and this is critical, you have to actually check that they're accurate. Article content That's assuming, of course, that we still know how to think for ourselves in 25 years. The stories you hear out of the education world about students relying on AI for their work — and struggling in vain to perform without it — are downright dystopian. Article content Article content Tales abound of students using AI to generate entire essays, and I often detect a tone of hopelessness among teachers and professors lamenting it. At the high-school level, I've heard stories of parents going to the wall to protect their kids who've been caught plagiarizing — and of teachers basically giving up the fight, because unlike traditional plagiarism, it can be difficult to prove conclusively that something is AI-generated. ChatGPT doesn't always give the same answers to the same questions, which sounds to me more like a bug than a feature … unless you're looking to plagiarize an essay, of course. Article content (I'm amused to see that Grammarly, the website that allowed an entire generation to opt out of learning how to write an English sentence, now provides a service that will flag AI-generated text. Pick a lane, fellas!) Article content The frustrating thing is, it's not remotely difficult to detect AI-generated text qualitatively once you're familiar with it. It is absolute trash, always, and immediately recognizable to anyone paying the slightest bit of attention: unrelentingly bland, often repetitive, punctuated by weird verbs and jarring turns of phrase. Teachers in particular, who will (hopefully!) know how a student actually writes, will take notice when that student submits something completely out of character. Article content 'Beyond a reasonable doubt' shouldn't be the standard for implementing academic sanctions. But if flagging AI plagiarism is too much too ask, there is a very easy solution: In-person, handwritten exams. Schools and individual teachers and professors are increasingly resorting to that — and finding that many of their students have no idea how to write, both structurally and in terms of penmanship. Article content
